Table 1B.
Patient ID | FGFR2 Fusion | Post-Progression BGJ398/Debio1347, Prior to TAS-120 | Post-Progression TAS-120 | ||
---|---|---|---|---|---|
cfDNA | Tumor Biopsy | cfDNA | Tumor Biopsy | ||
1 | FGFR2-SORBS1 | K660M, K715R | None Detected | V565F& | V565F&& |
2 | FGFR2-ZMYM4 | V565F, K660M, E566A, N550H, N550K | V565F&&, K660M&& | V565F, K660M, E566A, N550H, N550K, V563L | V563L |
3 | FGFR2-INA | H683L&, L618V& | Biopsy #1: H683L Biopsy #2: N550H, N550T, M538I |
V565L, E566A, N550H, L618V, N550T&, M538I& | No Biopsy Obtained |
4 | FGFR2-NRAP | None Detected | No Biopsy Obtained | N550K | N550K |
All mutations were detected on CLIA-certified assays as a routine part of clinical care except those designated with an &(detected on ddPCR only) or &&(detected on WES only).